2017 Press Releases

Keyword Search
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
05/25/2017OpGen to Present Advancements in Antibiotic Susceptibility and Whole Genome Sequencing at ASM Microbe 2017
GAITHERSBURG, Md., May 25, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that data on its Acuitas® Rapid Test in development and Acuitas Whole Genome Sequence Analysis will be presented at ASM Microbe 2017 being held June 1-5, 2017 in New Orleans, LA. These data will demonstrate the company’s ability to predict phenotypic resistance across antibiotic classes for Gram-negative infections using rapid genetic testing and predictive algorithms from its Acuitas Lighthouse® Know... 
 Printer Friendly Version
04/27/2017OpGen Appoints Tina S. Nova, Ph.D. to Board of Directors
GAITHERSBURG, Md., April 27, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that Tina S. Nova, Ph.D. has been appointed to its Board of Directors.   Dr. Nova is a life science industry veteran with extensive experience building and leading novel genomics-based businesses. She currently serves as president and chief executive officer of Molecular Stethoscope, Inc., a newly formed molecular diagnostics company. Most recently, she was senior vice president and general manag... 
 Printer Friendly Version
04/26/2017OpGen Announces 2017 First Quarter Financial Results
GAITHERSBURG, Md., April 26, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today reported financial and operational results for the first quarter ended March 31, 2017 and summarized recent business highlights. “In the first quarter, we presented preliminary results supporting the Acuitas® Rapid Test in development for detection of resistance genes in multi-drug resistant pathogens and demonstrated the bioinformatics capabilities of the Acuitas Lighthouse® Knowledgebase to predict antib... 
 Printer Friendly Version
04/25/2017OpGen Highlights Capabilities of its Acuitas® Technologies to Rapidly Predict Antibiotic Susceptibility Using Drug Resistance Gene Profiles at ECCMID
GAITHERSBURG, Md., April 25, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it has presented preliminary results supporting its Acuitas Rapid Test in development to detect antibiotic resistant genes and the use of predictive algorithms from its Acuitas Lighthouse® Knowledgebase to predict antibiotic susceptibility. The results were presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria. The poster, titled... 
 Printer Friendly Version
04/19/2017OpGen Announces Date of First Quarter 2017 Financial Results Conference Call
GAITHERSBURG, Md., April 19, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will report its first quarter 2017 financial results after close of market on Wednesday, April 26, 2017. OpGen’s management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the company’s financial results and business progress. Dial-in Information U.S. Dial-In Number: 844-420-8185 International Dial-In Number: 216-562-0481 Conference ID: 11373581 ... 
 Printer Friendly Version
04/13/2017OpGen to Present Antibiotic Resistance Prediction Data at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
GAITHERSBURG, Md., April 13, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that five posters featuring its technologies will be presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 22-25, 2017 in Vienna, Austria. Among them will be a poster presentation titled "Prediction of antibiotic resistance in Escherichia Coli from resistance genes" by Dr. Terry Walker, Senior Vice President of Research and Development at Op... 
 Printer Friendly Version
04/13/2017OpGen to Present Antibiotic Resistance Prediction Data at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
GAITHERSBURG, Md., April 13, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that five posters featuring its technologies will be presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 22-25, 2017 in Vienna, Austria. Among them will be a poster presentation titled “Prediction of antibiotic resistance in Escherichia Coli from resistance genes” by Dr. Terry Walker, Senior Vice President of Research and Development at ... 
 Printer Friendly Version
03/23/2017OpGen Announces 2016 Fourth Quarter and Year End Financial Results
Achieves Revenue of Approximately $4.0 Million, a 27% Year Over Year Increase GAITHERSBURG, Md., March 23, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today reported financial and operational results for the fourth quarter and year ended December 31, 2016 and summarized 2016 business highlights.  Total revenue for the full year ended December 31, 2016 was $4.0 million, a 27% increase from $3.2 million recorded for the full year ended December 31, 2015.  Net loss for the full year ended... 
 Printer Friendly Version
03/16/2017OpGen Announces Date of 2016 Fourth Quarter and Year End Financial Results Conference Call
GAITHERSBURG, Md., March 16, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will report its 2016 fourth quarter and year end financial results after close of market Thursday, March 23, 2017. OpGen’s management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the company’s financial results and recent developments. Dial-in Information U.S. Dial-In Number: 844-420-8185 International Dial-In Number: 216-562-0481 Conference ID... 
 Printer Friendly Version
03/01/2017OpGen to Present at the Cowen and Company 37th Annual Health Care Conference
GAITHERSBURG, Md., March 01, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that Evan Jones, the Company’s Chairman and Chief Executive Officer, will present a corporate overview at the Cowen and Company Health Care Conference on Tuesday, March 7, 2017 at 10:40 a.m. Eastern time. The conference is being held from March 6-8 in Boston, MA. To listen to the presentation live, investors may visit the investor relations section of OpGen, Inc.’s website at www.opgen.com. An ar... 
 Printer Friendly Version
02/14/2017OpGen Presents Rapid Acuitas Genetic Test Data at Advances in Genome Biology and Technology Meeting
Data support ability to predict antibiotic susceptibility in hours instead of days GAITHERSBURG, Md., Feb. 14, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced preliminary data demonstrating the ability to rapidly and accurately predict bacterial antibiotic susceptibility using resistance gene profiles. The data were presented at the Advances in Genome Biology and Technology (AGBT) meeting, which is taking place from February 13-16, 2017 in Hollywood Beach, FL. These prelimi... 
 Printer Friendly Version
01/26/2017OpGen Reports Preliminary Fourth Quarter and Full Year 2016 Financial Results
Achieves Revenue of Approximately $4.0 Million, a 27% Year Over Year Increase GAITHERSBURG, Md., Jan. 26, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced preliminary unaudited results for the fourth quarter and full year ended December 31, 2016, and summarized 2016 business highlights.  Total revenue for the full year ended December 31, 2016 was approximately $4.0 million, a 27% increase from the $3.2 million recorded for the full year ended December 31, 2015. Total revenue... 
 Printer Friendly Version